Acurx Pharmaceuticals, Inc.

STATEN ISLAND, NY · Founded 2017 · CIK 0001736243 · Biotech · Private

Novel antibiotics targeting priority pathogenic bacteria, currently in Phase 2b development for C. difficile infection treatment

acurxpharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$17M
7 Form D · Apr 2026
5 months since last filing
Contracts
—
No federal contracts on record
Patents
11
2 granted · 9 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,081,500
Private capital raisedForm D · SEC$455,000
Private capital raisedForm D · SEC$2,404,259
Private capital raisedForm D · SEC$3,376,350
Private capital raisedForm D · SEC$12,000,000
Private capital raisedForm D · SEC$3,978,664
Private capital raisedForm D · SEC$4,587,473
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2301Basking Biosciences—$29M
2302GALATEA BIO INC—$3.7M
2303Relay Therapeutics—$30M
2304Acurx Pharmaceuticals, Inc.—$17M
2305Congruence Therapeutics——
2306BICYCLE THERAPEUTICS PLC—$555M
2307Gatehouse Bio, Inc.—$5.4M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 22 related persons
  • Paul BaehrDirector
  • Jack DeanDirector
  • JACK DEANDirector
  • Robert DeLucciaDirector · Executive Officer
  • ROBERT DELUCCIADirector · Executive Officer
  • James DonohueDirector
  • JAMES DONOHUEDirector
  • Michael DuffyDirector
  • Thomas HarrisonDirector
  • THOMAS HARRISONDirector
  • Anthony JadhonDirector
  • Katie JadhonDirector
  • David LuciDirector · Executive Officer
  • DAVID LUCIDirector · Executive Officer
  • Mark RathjenDirector
  • Carl SailerDirector
  • CARL SAILERDirector
  • Joseph ScodariDirector
  • JOSEPH SCODARIDirector
  • Robert ShawahExecutive Officer
  • ROBERT SHAWAHExecutive Officer
  • John TerranaDirector

Patents

USPTO · 2 granted of 11
  • Compounds and Methods for Improving Healthapplication
  • DNA Polymerase IIIC Inhibitors and Use Thereofgranted
  • Use of Ibezapolstat to Promote Microbiome Healthapplication
  • Use of Ibezapolstat to Promote Microbiome Healthgranted
  • Compounds and Methods for Improving Microbiome Healthapplication
  • Compounds And Methods For Improving Microbiome Healthapplication
  • Compounds and Methods for Improving Microbiome Healthapplication
  • Compounds And Methods For Improving Healthapplication
  • Inhibitors of DNA Polymerase IIIC in Gram-Positive Bacteria, Pharmaceutical Compositions Thereof, and Uses Thereofapplication
  • Inhibitors of DNA Polymerase IIIC in Gram-Positive Bacteria, Pharmaceutical Compositions Thereof, and Uses Thereofapplication
  • Inhibitors Of Dna Polymerase Iiic In Gram-positive Bacteria, Pharmaceutical Compositions Thereof, And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.